Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges

Lung cancer is the most common cancer and the leading cause of cancer death worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018. Although small cell lung cancer (SCLC) is the most aggressive type of lung cancer, it shows high response rates to chemotherapy in early line...

Descripción completa

Detalles Bibliográficos
Autores principales: Regzedmaa, Orgilmaa, Zhang, Hongbing, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580132/
https://www.ncbi.nlm.nih.gov/pubmed/31354294
http://dx.doi.org/10.2147/OTT.S204577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580132/
https://www.ncbi.nlm.nih.gov/pubmed/31354294
http://dx.doi.org/10.2147/OTT.S204577

Ejemplares similares